Humacyte announces presentation of two-year results from V007 Phase 3 trial

Humacyte (HUMA) announced the presentation of positive two-year results from the V007 Phase 3 clinical trial of the acellular tissue engineered vessel in arteriovenous access for hemodialysis patients at the American Society of Nephrology’s Kidney Week 2025, the premier nephrology meeting, in Houston. In the V007 Phase 3 trial, the ATEV was observed to have superior duration of use over 24 months as compared to autogenous fistula in female, obese and diabetic patients. Autogenous fistula is the current gold standard for hemodialysis access across all patients. However, female, obese and diabetic patients comprise high-need subgroups, having historically poor outcomes with AV fistula procedures. Key points: The ATEV was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures; The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients